Renaissance of farnesyltransferase inhibitors in cancer
József Tímár, Balázs Hegedűs, Marcell Baranyi · 2026
Read Renaissance of farnesyltransferase inhibitors in cancer by József Tímár, Balázs Hegedűs, Marcell Baranyi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13422314.txt.
Description
József Tímár and colleagues review the comeback of farnesyltransferase inhibitors in cancer in a 2026 paper. Early trials failed because the drugs were given without markers to pick responders, stalling the field. Two approvals revived interest, lonafarnib for childhood progeria and tipifarnib for HRAS-mutant head and neck cancer.
New lab work shows these inhibitors can boost KRAS blockers and other targeted drugs, giving the class a second chance in combination therapy. The review insists future trials must use predictive markers, or they risk repeating the first generation's costly mistake.
Catalog record
| CREATOR | József Tímár, Balázs Hegedűs, Marcell Baranyi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |